• Exciting News: Interview with Our CTO on Revolutionary Blood Clot Treatment
We are thrilled to announce that our Chief Technology Officer, Keitaro Yoshimoto, was recently featured in an interview with Drug Discovery News, discussing groundbreaking advancements in synthetic DNA for safer blood clot treatments. The full article can be read here.

• Breakthrough Anticoagulant Treatment Showcases Power of MACE® Technology (LinkBIO.Co.LTD Patent)
The recent news release by the University of Tokyo unveils a groundbreaking DNA-based anticoagulant therapy. (August 22, 2023)

• Our researcher, Osman Waleed, and Tokyo University’s CTO, Associate Professor Keitaro Yoshimoto, have announced their research achievement entitled “Steric hindrance and structural flexibility shape the functional properties of a guanine-rich oligonucleotide” published in Nucleic Acids Research with an impact factor of 19. (August 1, 2023)

• We have published our new research paper to prove the efficiency of our MACE SELEX Technology for the selection of highly specific DNA Aptamer for small molecules target. (Dec 02, 2022)

• LinkBIO and Nara Medical University have signed a “Joint Research and Development Agreement for the Treatment of Blood Diseases”. (July 25, 2022)